However, another study comparing 45 AD and 36 control subjects reported low BACE1-AS in the pre-AD stage, while these levels dramatically increased in the full-AD condition, thus excluding the possibility of an early diagnosis, and showing the importance of distinguishing the disease stage when designing a screening study [258]. This evidence concerns the gene BACE1 and Alzheimer disease.